XML 45 R28.htm IDEA: XBRL DOCUMENT
v3.25.3

Equity | 12 Months Ended
--- | ---
Jul. 31, 2025
Equity [Abstract] |
EQUITY | NOTE 24 – EQUITY Share Repurchase Program Effective April 14, 2023, the Company’s Board of Directors approved a share repurchase program (the “2023 Share Repurchase Program”) authorizing the repurchase of up to $5 million of the Company’s Class B common stock. Under the 2023 Share Repurchase Program, the Company was authorized to purchase, at purchase prices up to $1.75 per share, shares of its Class B common stock from time to time until June 16, 2023 (the “Plan Termination Date”). In July 2023, the 2023 Share Repurchase Program was amended to extend the Plan Termination Date to July 1, 2024. The Company has repurchased 101,487 of its Class B common stock for a total cost of $168 thousand under the 2023 Share Repurchase Program. On December 22, 2023, the Company suspended the share repurchase program through the Plan Termination Date. Class A Common Stock and Class B Common Stock The rights of holders of Class A common stock and Class B common stock are identical except for certain voting and conversion rights and restrictions on transferability. The holders of Class A common stock and Class B common stock receive identical dividends per share when and if declared by the Company’s Board of Directors. In addition, the holders of Class A common stock and Class B common stock have identical and equal priority rights per share in liquidation. The Class A common stock and Class B common stock do not have any other contractual participation rights. The holders of Class A common stock are entitled to three votes per share and the holders of Class B common stock are entitled to one-tenth of a vote per share. Each share of Class A common stock may be converted into one share of Class B common stock, at any time, at the option of the holder. Shares of Class A common stock are subject to certain limitations on transferability that do not apply to shares of Class B common stock. On May 27, 2021, the Company filed a Registration Statement on Form S-3, whereby the Company may sell up to $250 million of Class B common stock. This Registration Statement was declared effective on June 7, 2021. On June 1, 2021, the Company filed a Registration Statement on Form S-3 to issue 48,859 shares of Class B common stock for payment due on the purchase of Altira, an investment which has been subsequently fully impaired. On August 19, 2021, the Company entered into a Securities Purchase Agreement (the “Institutional Purchase Agreement”) with certain third-party institutional investors (the “Institutional Investors”) and a Securities Purchase Agreement with I9Plus, LLC (the “Jonas Purchase Agreement”), an entity affiliated with Howard S. Jonas, the Chairman of the Board of Directors of the Company. On August 24, 2021, the Company issued 2,833,425 shares of Class B common stock (the “Institutional Shares”), par value $0.01 per share, to the Institutional Investors, at a purchase price equal to $35.00 per share, for aggregate gross proceeds of approximately $99.2 million, before deducting placement agent fees and other offering expenses. Additionally, pursuant to the Jonas Purchase Agreement, the Company issued 112,501 shares of Class B common stock to I9Plus, LLC, at a purchase price equal to $44.42 per share, which was equal to the closing price of a share of the Class B common stock on the New York Stock Exchange on August 19, 2021 (the “Jonas Offering”). The Jonas Offering resulted in additional aggregate gross proceeds of approximately $5.0 million. The total net proceeds from the issuance of shares were $98.0 million after deducting transaction costs of $6.2 million. On August 19, 2021, in connection with the Institutional Purchase Agreement, the Company entered into a Registration Rights Agreement with the Institutional Investors whereby the Company agreed to prepare and file a registration statement with the SEC within 30 days after the earlier of (i) the date of the closing of the Merger Agreement, and (ii) the date the Merger Agreement is terminated in accordance with its terms, for purposes of registering the resale of the Institutional Shares and any shares of Class B common stock issued as a dividend or other distribution with respect to the Institutional Shares. On February 15, 2022, the Company filed a Registration Statement on Form S-3 (as amended on March 2, 2022) registering the resale by the Institutional Investors of the shares purchased by them. The Registration Statement was declared effective on March 7, 2022. In March 2018, the Company established its 2018 Equity Incentive Plan. On January 19, 2022, the Company’s stockholders approved the 2021 Equity Incentive Plan (the “2021 Plan”). The 2018 Equity Incentive Plan was suspended and replaced by the 2021 Plan and, following January 19, 2022, no new grants are to be awarded under the 2018 Equity Incentive Plan. Existing grants under the 2018 Equity Incentive Plan will not be impacted by the adoption of the 2021 Plan. Any of the Company’s employees, directors, consultants, and other service providers, and those of the Company’s affiliates, are eligible to participate in the 2021 Plan. In accordance with applicable tax rules, only employees (and the employees of parent or subsidiary corporations) are eligible to be granted incentive stock options. The 2021 Plan authorizes stock options (both incentive stock options or non-qualified stock options), stock appreciation rights, restricted stock, restricted stock units, and cash or other stock-based awards. On January 19, 2022, the Company filed a Registration Statement on Form S-8 registering 1,919,025 shares of Class B common stock reserved for issuance under the 2021 Plan. On November 28, 2022, the Company’s Board of Directors approved an amendment to the 2021 Plan that, among other things, increases the number of shares of the Company’s Class B common stock available for the grant of awards thereunder by an additional 696,770, which the stockholders approved on January 23, 2023. On January 9, 2025, the Company’s Board of Directors approved an amendment to the 2021 Plan that, among other things, increases the number of shares of the Company’s Class B common stock available for the grant of awards thereunder by an additional 750,000, which the stockholders approved on January 13, 2025. The maximum number of shares of Class B common stock that may be issued under the 2021 Plan is 3,365,795 shares. As of July 31, 2025, there were 153,879 shares still available for issuance under the 2021 Plan. On July 6, 2022, pursuant to the I9 SPA dated June 22, 2022 with I9 Plus, LLC, an entity affiliated with members of the family of Howard Jonas, the Company sold 3,225,806 shares of the Company’s Class B common stock to I9 Plus, LLC at a price per share of $1.86 and an aggregate sale price of $6 million. Employment Agreement On June 13, 2022, the Company entered into an employment agreement with Howard S. Jonas (who serves as the Chairman of the Board and Executive Chairman of the Company) (the “Employment Agreement”), which provides, among other things: (i) a term of five years (subject to extension unless either party elects not to renew); (ii) an annual base salary of $260,000, of which $250,000 is payable through the issuance of restricted shares of the Company’s Class B common stock with the value of the shares based upon the volume weighted closing price of the Class B Stock on the NYSE on the thirty days ending with the NYSE trading day immediately preceding the issuance to be issued within thirty days of the date of the Employment Agreement (the “Start Date”) and each annual anniversary, and such shares vesting, contingent on Mr. Jonas’ remaining in continuous service to the Company, in substantially equal amounts on the three, six, nine and twelve month anniversaries of the Start Date or annual anniversary; and (iii) a grant of restricted shares of Class B common stock with a value of $600,000, issuable within 30 days with the value of the shares based upon the volume weighted closing price of the Class B common stock on the NYSE on the 30 days ending with the NYSE trading day immediately preceding the issuance and such shares, and vesting, contingent on Mr. Jonas remaining in continuous service to the Company, in substantially equal amounts on the first and second annual anniversaries of the Start Date. On June 19, 2024, the Employment Agreement was amended to provide an annual base salary of $294,000, of which $250,000 is payable through the issuance of Class B common stock in accordance with the terms defined above. Stock Options A summary of stock option activity for the Company is as follows:
|  | Number of Options |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (in years) |  |  | Aggregate Intrinsic Value (in thousands) |
Outstanding at July 31, 2024 |  |  | 638,409 |  |  | $ | 9.55 |  |  |  | 8.39 |  |  | $ | — |
Rollover Options |  |  | 618,702 |  |  |  | 5.84 |  |  |  | 8.30 |  |  |  |  |
Granted |  |  | 395,000 |  |  |  | 1.98 |  |  |  | 9.65 |  |  |  | — |
Expired |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Cancelled / Forfeited |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Outstanding at July 31, 2025 |  |  | 1,652,111 |  |  | $ | 6.65 |  |  |  | 8.26 |  |  | $ | — |
Exercisable at July 31, 2025 |  |  | 371,846 |  |  | $ | 14.94 |  |  |  | 6.86 |  |  | $ | — |
At July 31, 2025, there were unrecognized compensation costs related to non-vested stock options of $0.9 million, which are expected to be recognized over the next 3.7 years. The determination of the fair value of options granted during the year ended July 31, 2025 used the following weighted average assumptions and key inputs:
|  | July 31, 2025 |
Risk-free interest rate |  |  | 4.10 | %
Expected term (in years) |  |  | 6.25 |
Expected volatility |  |  | 87 | %
Expected dividend yield |  |  | — | %
The weighted average fair value per share of stock options granted for the year ended July 31, 2025 was $1.50. As part of the Cyclo Merger, Historical Cyclo Options to purchase Cyclo Common Stock, issued under Cyclo’s 2021 Equity Incentive Plan, that were outstanding immediately prior to the Merger were converted into options to purchase, on substantially similar terms and conditions, 618,702 shares of Rafael’s Class B common stock at an adjusted exercise price per share based upon the Exchange Ratio (the “Rollover Options”). Rafael Medical Devices Stock Options The Rafael Medical Devices 2022 Equity Incentive Plan (the “RMD 2022 Plan”) was created and adopted by the Company in May 2022. The RMD 2022 Plan allows for the issuance of up to 10,000 shares of Class B common stock which may be awarded in the form of incentive stock options or restricted shares. In connection with the conversion of Rafael Medical Devices from a Delaware corporation to a Delaware limited liability company, Rafael Medical Devices adopted the Rafael Medical Devices, LLC 2023 Equity Incentive Plan (the “RMD 2023 Plan”) in August 2023. The RMD 2023 Plan allows for issuance of up to 46,125 Class A Units. There were 16,872 Units available for issuance under the RMD 2023 Plan as of July 31, 2025. Rafael Medical Devices, LLC records compensation expense for stock-based awards based upon an assessment of the grant date fair value for options using the Black-Scholes model. The expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, characteristics from comparable companies are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards. The risk-free interest rate is determined by reference to the U.S. Treasury Constant Maturity Treasury rates with remaining maturities similar to the expected term of the options. Expected dividend yield is zero as Rafael Medical Devices, LLC has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. A summary of option activity for Rafael Medical Devices, LLC is as follows:
|  | Number of Options |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (in years) |  |  | Aggregate Intrinsic Value (in thousands) |
Outstanding at July 31, 2024 |  |  | 43,878 |  |  | $ | 10.00 |  |  |  | 9.01 |  |  | $ | — |
Cancelled / Forfeited |  |  | (14,625 | ) |  |  | 10.00 |  |  |  | 9.01 |  |  |  | — |
Outstanding at July 31, 2025 |  |  | 29,253 |  |  | $ | 10.00 |  |  |  | 8.01 |  |  | $ | — |
Exercisable at July 31, 2025 |  |  | 16,228 |  |  | $ | 10.00 |  |  |  | 8.01 |  |  | $ | — |
At July 31, 2025, the total unrecognized compensation related to stock option awards granted was $106 thousand, which the Company expects to recognize over a weighted average period of approximately 2.0 years. Cornerstone Stock Options Cornerstone has outstanding stock options and non-qualified options to purchase Cornerstone’s common stock which were granted under Cornerstone’s 2009 and 2018 Stock Incentive Plans (the “Plans”), as well as additional options issued during a prior capital raise. At July 31, 2025, there were 1,004,341 options outstanding granted under the Plans that are vested with a weighted average exercise price of $24.17 per share and a weighted average remaining contractual term of 4.4 years. The fair value of outstanding options granted under the Plans assumed during the Cornerstone Acquisition were determined to be de minimis. In connection with Cornerstone’s 2003 common stock offerings, Cornerstone entered into an option agreement with an individual in connection with identifying investors. The option agreement grants the right to purchase an option (a “Purchase Option”) to purchase 472,000 Class A Options (“Class A Options”), which allows the purchase of 0.25 shares of common stock for each Class A Option at $11.00 per share. In order to secure this Class A Option, a Purchase Option must initially be purchased for $.005 per potential share of Class A options. Upon exercise of each Class A Option, a right is granted to one Class B Option (“Class B Options”), which allow the purchase of 0.25 shares of common stock for each Class B Option at $12.50 per share. The expiration date of the Class A Options is the later of October 29, 2005 or six months from the date the Company’s shares become publicly traded. The Class B Options expire 180 days from the exercise of the Class A Options. In 2003, 625,000 options (the “Cornerstone Common Options”) were granted with an exercise price of $11.00 per share to a 2003 investor. These Cornerstone Common Options are set to expire 180 days following the closing of an IPO, or from the date Cornerstone’s shares become publicly traded. The fair value of the Class A Options, Class B Options, and Cornerstone Common Options assumed during the Cornerstone Acquisition were determined to be de minimis. As part of the Cornerstone Restructuring, as detailed in Note 3, Cornerstone increased the available reserve of Cornerstone Common Stock for grant to employees, consultants and other service providers to approximately 10% of Cornerstone’s capital stock following the Cornerstone Restructuring, the Mandatory Common Conversion and the Reverse Stock Split (the “Reserve Increase”) but prior to the issuance of the RPF 6% Top Up Shares or any shares to the holders of the Remaining Series C Convertible Notes after the Closing. Replacement Warrants As part of the Merger with Cyclo, all outstanding warrants to purchase Cyclo Common Stock (other than those held by Rafael, which were cancelled, and those which were settled in cash) were automatically converted into warrants to purchase 1,087,100 shares of Rafael Class B common stock, at an adjusted exercise price per share based upon the Exchange Ratio. The following table presents the number of common stock warrants outstanding:
Replacement Warrants issued as part of the Cyclo Merger on March 25, 2025 |  |  | 1,087,100 |
Expired |  |  | (28,198 | )
Warrants outstanding, July 31, 2025 |  |  | 1,058,902 |
The following table presents the number of common stock warrants outstanding, their exercise price, and expiration dates as of July 31, 2025 (the names below refer to the related Cyclo transaction prior to the Merger):
Name |  | Warrants Issued |  |  | Exercise Price |  |  | Expiration Date
December 2018 Units Offering Warrant |  |  | 12,407 |  |  | $ | 184.41 |  |  | 12/21/2025
Placement Agent Warrants April 2020 Think Equity Tail |  |  | 783 |  |  | $ | 31.21 |  |  | 9/27/2025
August 2020 PIPE Warrant |  |  | 64,543 |  |  | $ | 42.56 |  |  | 8/27/2027
2020 Public Offering |  |  | 380,253 |  |  | $ | 14.19 |  |  | 12/11/2025
Placement Agent Warrants December 2020 Maxim |  |  | 20,268 |  |  | $ | 17.73 |  |  | 12/11/2025
April 2023 PIPE Warrants |  |  | 253,280 |  |  | $ | 2.01 |  |  | 4/20/2030
October 2023 Warrant Exchange |  |  | 327,368 |  |  | $ | 2.70 |  |  | 10/23/2027
|  |  | 1,058,902 |  |  |  |  |  |  |
Restricted Stock The fair value of restricted shares of the Company’s Class B common stock is determined based on the closing price of the Company’s Class B common stock on the grant date. Share awards generally vest on a graded basis over three to four years of service. In January 2022, the Company granted 33,360 restricted shares of Class B common stock to non-employee directors, 18,336 of which were granted under the 2018 Equity Incentive Plan, and 15,024 of which were granted under the 2021 Plan. The restricted shares vested immediately on the grant date. The share-based compensation cost was approximately $151 thousand, which was included in general and administrative expense in the consolidated statements of operations and comprehensive loss. On February 1, 2022, the Company issued 986,835 shares of Class B restricted stock to two executive officers. Approximately 24% of the restricted shares vested in December 2022, with the remaining shares vesting ratably each quarter through December 2025. On June 14, 2022, the Company issued 452,130 shares of Class B restricted stock to Howard S. Jonas. In January 2023, the Company issued 120,019 shares of Class B restricted stock to certain members of its Board of Directors, and 100,000 shares of Class B restricted stock to its Chief Financial Officer. On August 28, 2023, the Company issued 111,408 shares of Class B restricted stock to Howard S. Jonas. On October 25, 2023, the Company issued 135,000 shares of Class B restricted stock to employees of the Company. On January 5, 2024, the Company issued 101,402 shares of Class B restricted stock to certain members of its Board of Directors. On June 13, 2024, the Company issued 159,016 shares of Class B restricted stock to Howard S. Jonas. On January 6, 2025, the Company issued 84,918 shares of Class B restricted stock to certain members of its Board of Directors. On January 13, 2025, the Company issued 270,000 shares of Class B restricted stock to employees and consultants of the Company. On June 13, 2025, the Company issued 118,596 shares of Class B restricted stock to Howard S. Jonas. On September 2, 2025, the Company issued 99,429 shares of Class B restricted stock to John Goldberg, a consultant of the Company. A summary of the status of the Company’s grants of restricted shares of Class B common stock is presented below:
|  | Number of Non-vested Shares |  |  | Weighted Average Grant Date Fair Value |
Outstanding at July 31, 2024 |  |  | 608,540 |  |  | $ | 2.99 |
Granted |  |  | 473,514 |  |  |  | 1.97 |
Cancelled / Forfeited |  |  | (31,875 | ) |  |  | 7.40 |
Vested |  |  | (633,459 | ) |  |  | 2.88 |
Non-vested shares at July 31, 2025 |  |  | 416,720 |  |  | $ | 1.99 |
At July 31, 2025, there was $0.6 million of total unrecognized compensation cost related to non-vested stock-based compensation arrangements, which is expected to be recognized over the next 3.5 years. A summary of the stock-based compensation expense for the Company’s equity incentive plans is presented below (in thousands):
|  | For the Year Ended July 31, |
|  | 2025 |  |  | 2024 |
General and administrative |  | $ | 1,962 |  |  | $ | 2,000 |
Research and development |  |  | 166 |  |  |  | 296 |
Forfeiture of RSUs within research and development |  |  | (5 | ) |  |  | — |
Total stock-based compensation expense, net of forfeitures |  | $ | 2,123 |  |  | $ | 2,296 |

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration